-

01:38:51 AM

QGEN Stock News

QGEN - Qiagen NV

07/01/21 1:59 AM

NYSE : QGEN

QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology

QIAGEN (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global strategic alliance with Japan’s Sysmex Corporation (Tokyo Stock Exchange, First Section [Ticker Code: 6869]) for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s

RHEA-AI

positive

06/29/21 4:07 PM

NYSE : QGEN

Verogen Partners with QIAGEN to Deliver Innovative Solutions for Human Identification Laboratories

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) and Verogen Inc. today announced a partnership to provide laboratories with superior tools and comprehensive support for implementing next-generation sequencing (NGS) human identification workflows.The partnership with QIAGEN is a

RHEA-AI

very positive

06/29/21 4:05 PM

NYSE : QGEN

QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing Solutions

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a commercialization partnership with San Diego-based human identification specialist Verogen that will provide customers of both companies with superior tools and comprehensive support for human identification (HID) workflows

RHEA-AI

positive

06/21/21 4:05 PM

NYSE : QGEN

QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the

RHEA-AI

neutral

05/28/21 1:45 PM

NYSE : QGEN

QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen ® KRAS RGQ PCR Kit ( therascreen KRAS Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in the

RHEA-AI

very positive

05/25/21 4:05 PM

NYSE, Nasdaq : QGEN, MRTX

QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)

QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced a global collaboration with Mirati Therapeutics Inc. (NASDAQ:MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRAS G12C mutation who may benefit from treatment

RHEA-AI

very positive

05/17/21 6:15 AM

NYSE : QGEN

management

QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the creation of a Scientific Advisory Board as well as updates on the Supervisory Board ahead of the Annual General Meeting in June 2021.Creation of new Scientific Advisory BoardThe Managing Board and Supervisory Boards of

RHEA-AI

neutral

05/12/21 4:05 PM

NYSE : QGEN

QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus Antibodies

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the fast and easy-to-use QIAreach ® Anti-SARS-CoV-2 Total Test.The authorization means QIAGEN can start making its

RHEA-AI

neutral

05/03/21 4:05 PM

NYSE : QGEN

QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year 2021

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced strong results of operations for the first quarter of 2021, exceeding the goals for net sales and adjusted earnings per share.Net sales in the first quarter of 2021 rose 52% (+48% at constant exchange rates, CER) to $567.2 million

RHEA-AI

neutral

04/29/21 4:05 PM

NYSE : QGEN

QIAGEN Announces EZ2 Connect Instrument Line for Automated Sample Processing in Research, Forensics and Diagnostics

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the upcoming launch of the EZ2 Connect product line, a next-level automated sample-processing platform whose simplicity, flexibility and speed will benefit biomedical research, forensics and clinical diagnostics.The EZ2

RHEA-AI

very positive

Prev 1 2 3 4 5 6 7 8 9 Next

QGEN Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.qiagen.com
CeoThierry Bernard
Security nameQiagen NV
Issue typecs
SectorManufacturing
Sic code2836
Employees5610
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressHulsterweg 82
StateLimburg
CityVenlo
Zip5912 PL
CountryNetherlands
Phone31773556600

About Qiagen NV

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2020, QIAGEN employed more than 5,600 people in over 35 locations worldwide.